

## Disclosures

### Personal Commercial (14)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<b>Self</b>			
35 Pharma	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
AOP Orphan	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Ferrer	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Gossamer	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Keros	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Liquida	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Merck & Co., Inc.	Consultant Fees/Honoraria	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Novartis Corporation	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Regeneron	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Respira	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Roivant	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
United Therapeutics	Consultant Fees/Honoraria	Modest (< \$5,000)	Pulmonary Hypertension and Venous Thromboembolic

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

### Institutional Financial Decision-Making Role (0)

No disclosures on record

### Expert Witness Testimony (0)

No disclosures on record

<sup>†</sup> Commercial Funding Source | <sup>‡</sup> Trial Name

## Agreement

## **Confidentiality, Disclosure and Assignment Agreement** | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

## **Embargo** | Signed on 10/2/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

## **On-Going Obligation Agreement** | Signed on 10/2/2024

---

### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.